Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SGEN Seagen (SGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Seagen alerts: Email Address About Seagen Stock (NASDAQ:SGEN) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Seagen alerts:Sign Up Key Stats Today's Range$228.74▼$228.7450-Day Range$228.74▼$228.7452-Week Range$123.77▼$228.96Volume86 shsAverage Volume1.48 million shsMarket Capitalization$42.93 billionP/E RatioN/ADividend YieldN/APrice Target$229.00Consensus RatingHold Company OverviewSeagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.Read More… Kamala’s tax plan is worse than you think—find out why (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Seagen Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 14th PercentileSeagen scored higher than 14% of companies evaluated by MarketBeat, and ranked 929th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingSeagen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSeagen has received no research coverage in the past 90 days.Read more about Seagen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SGEN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Sustainability and ESG2.5 / 5Environmental Score-2.86 Short InterestThere is no current short interest data available for SGEN. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for SGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Seagen to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seagen's insider trading history. Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Stock News HeadlinesPfizer: Turning The Corner (Rating Upgrade)May 27, 2024 | seekingalpha.comTwo Brothers, a Big Biotech Bet and an $8 Billion PayoutApril 13, 2024 | wsj.comKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.September 25, 2024 | Genesis Gold Group (Ad)Ron Baron Portfolio Magic: Building Your Financial FutureMarch 20, 2024 | msn.comBailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving marketsMarch 13, 2024 | msn.comPfizer shutting down Seagen's $350M construction project in EverettMarch 1, 2024 | bizjournals.comNeuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk SaysFebruary 24, 2024 | finance.yahoo.comMRNA Feb 2024 64.000 putFebruary 23, 2024 | finance.yahoo.comSee More Headlines SGEN Stock Analysis - Frequently Asked Questions How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The company's quarterly revenue was up 27.1% on a year-over-year basis. Does Seagen have any subsidiaries? Seagen subsidiaries include Cascadian Therapeutics. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM) and Tesla (TSLA). Company Calendar Last Earnings11/01/2023Today9/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees3,256Year Founded1998Price Target and Rating Average Stock Price Target$229.00 High Stock Price Target$229.00 Low Stock Price Target$229.00 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-610,310,000.00 Net Margins-32.61% Pretax Margin-32.12% Return on Equity-28.06% Return on Assets-20.92% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.12 Sales & Book Value Annual Sales$2.30 billion Price / Sales18.66 Cash FlowN/A Price / Cash FlowN/A Book Value$15.10 per share Price / Book15.15Miscellaneous Outstanding Shares187,698,000Free Float139,084,000Market Cap$42.93 billion OptionableOptionable Beta0.32 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report This page (NASDAQ:SGEN) was last updated on 9/25/2024 by MarketBeat.com Staff From Our PartnersCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinVenture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one littl...Crypto 101 Media | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.